Budget Impact Analysis of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections in Three European Countries

[1]  Timothy R. Pasquale,et al.  Novel developments in the treatment of acute bacterial skin and skin structure infections , 2019, Expert opinion on pharmacotherapy.

[2]  A. Pana,et al.  Economic evaluation of the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) from the national payer perspective: introduction of a new treatment to the patient journey. A simulation of three European countries , 2019, Expert review of pharmacoeconomics & outcomes research.

[3]  Á. Soriano,et al.  Dalbavancin in the treatment of different gram-positive infections: a real-life experience. , 2017, International journal of antimicrobial agents.

[4]  M. Bassetti,et al.  The role of dalbavancin in skin and soft tissue infections , 2018, Current opinion in infectious diseases.

[5]  L. Hurtado-López,et al.  Management of acute bacterial skin and skin structure infections with a focus on patients at high risk of treatment failure , 2017, Therapeutic advances in infectious disease.

[6]  S. Tsiodras,et al.  What is new in the management of skin and soft tissue infections in 2016? , 2017, Current opinion in infectious diseases.

[7]  N. Ampel,et al.  2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  F. Violi,et al.  Acute bacterial skin and skin structure infections in internal medicine wards: old and new drugs , 2016, Internal and Emergency Medicine.

[9]  Hien H. Nguyen,et al.  Acute bacterial skin and skin structure infections (ABSSSI): practice guidelines for management and care transitions in the emergency department and hospital. , 2015, The Journal of emergency medicine.

[10]  Markus Kraus,et al.  Efficiency, ownership, and financing of hospitals: The case of Austria , 2014, Health care management science.

[11]  A. Amin,et al.  Hospitalist perspective on the treatment of skin and soft tissue infections. , 2014, Mayo Clinic proceedings.

[12]  Jan V Hirschmann,et al.  Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  M. Wilcox,et al.  Once-weekly dalbavancin versus daily conventional therapy for skin infection. , 2014, The New England journal of medicine.

[14]  D. Talan,et al.  Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines. , 2013, The Journal of emergency medicine.

[15]  M. Bozhkova,et al.  Trends in the development of problematic antimicrobial resistance in the most important causative agents of bacteremias in the University Hospital "Sv. Marina" - Varna for the period 2007-2011 as a part of the European Antimicrobial Resistance Surveillance Network (EARS-Net). , 2013 .

[16]  M. Bassetti,et al.  How complicated skin and soft tissue infections are treated in Italy: economic evaluation of inpatient intravenous antibiotic treatment in seven hospitals , 2008, Journal of medical economics.

[17]  Ronald N. Jones,et al.  Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). , 2007, Diagnostic microbiology and infectious disease.

[18]  Roberta B Carey,et al.  Methicillin-resistant S. aureus infections among patients in the emergency department. , 2006, The New England journal of medicine.

[19]  Patchen Dellinger,et al.  Practice guidelines for the diagnosis and management of skin and soft-tissue infections. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  D. Nathwani.  Impact of methicillin-resistant Staphylococcus aureus infections on key health economic outcomes: does reducing the length of hospital stay matter? , 2003, The Journal of antimicrobial chemotherapy.